Tax Residency and Treaty Tie-Breaker

One of the most misunderstood areas in Israel-U.S. tax planning is corporate residency and the consequences can be significant.

In Israel, a company is considered a tax resident not only if it is incorporated locally, but also if its management and control are exercised from Israel. In contrast, the U.S. determines corporate residency primarily based on place of incorporation, taxing U.S. entities on their worldwide income.

This difference creates a real risk: a company can unintentionally be treated as a tax resident in both jurisdictions at the same time.

Unlike many other treaties, the Israel-U.S. tax treaty does not provide a clear corporate tie-breaker rule. In practical terms, this means that a dual-resident company may lose access to most treaty benefits, increasing exposure to double taxation.

While individuals can rely on “center of vital interests” tests to resolve residency conflicts, companies do not have the same flexibility.

The implication is straightforward: companies must be deliberate about where management decisions are made and documented. A U.S.-incorporated company effectively managed from Israel, for example, may face dual residency and with it, significant tax inefficiencies, unless properly structured and managed in advance.

Permanent Establishment (PE) Risks

Under most tax treaties (OECD Art.5), a PE arises from a fixed place of business or a dependent agent (e.g. office, branch, construction project over ~12 months, or an agent habitually concluding contracts). Israel’s domestic law is stricter: any Israeli-source business can be taxed, and having even one Israeli-based remote employee or contractor can trigger a PE and corporate tax obligations. Once a PE exists, Israel taxes profits attributable to it at 23% (plus interest/penalties from formation date), and also requires VAT registration (18%) and payroll compliance for local hires.

Example: A U.S. start-up sending an engineer to visit Israeli clients (or hiring a local sales rep) may create an Israeli PE. Likewise, an Israeli parent company with a long-term local distributor or R&D lab in the U.S. can establish U.S. ECI (effectively connected income) even without a U.S. subsidiary.
Common mistakes: Assuming no formal Israeli entity means no tax. In reality, sales activities, persistent marketing, or servicing Israeli customers often cross into taxable presence.

Withholding Taxes (WHT)

Israel imposes source-based withholding on payments to nonresidents: 25% on dividends, 15% on interest, 30% on royalties. The treaty caps these rates. For Israeli-source dividends to U.S. residents the treaty allows up to 25% (the same as domestic) but reduces to 12.5% if the U.S. recipient owns ≥10% of the paying Israeli company. If the Israeli payer is in a government-incentivized regime, the cap may be 15%. Interest from Israel to the U.S. is capped at 17.5% (10% if paid by banks), rather than the domestic 15%. Royalties (copyright, patents) are limited to 10–15% by treaty instead of 30%. (U.S. source withholding is often 0% for portfolio interest; the treaty reciprocates similar caps on U.S. payments to Israel.)

Practical tip: File the proper W-8BEN/E forms in the U.S. (or Israeli equivalent) to claim treaty rates. Neglecting to do so can result in over-withholding and cash flow loss.

Transfer Pricing Documentation

Both Israel and the U.S. require related-party transactions to follow the arm’s-length principle. In Israel, companies must file Form 1385 detailing intercompany deals, and groups over ILS 150M (~$40M) must also maintain a Master File. U.S. rules don’t require filing, but documentation must support compliance.

Incomplete or outdated transfer pricing records are a common risk. CFOs should implement policies early, update benchmarks annually, and ensure all significant related-party transactions are documented promptly.

R&D Incentives (Israel and U.S.)

Israel encourages R&D mainly through grants from the Innovation Authority, covering 20 – 50% of approved costs (up to 75% for certain groups). While there’s no direct R&D tax credit, R&D expenses are deductible under standard tax rules. Special IP capital gains rates may apply for patent sales to foreign affiliates.

In the U.S., companies can claim a §41 R&D tax credit of about 20% of qualifying incremental spend. Small startups (gross receipts < $5M) can even offset payroll taxes – now up to $500K per year.

CFC Rules, GILTI and Foreign Tax Credit

For U.S. parent companies, Israeli subsidiaries are Controlled Foreign Corporations (CFCs) if U.S. owners have >10% stakes. Under the 2017 TCJA, certain Israeli-sourced income was subject to GILTI (Global Intangible Low-Taxed Income) inclusion at an effective 10.5% U.S. rate (after a 50% deduction), with only 80% of Israeli tax creditable. Starting 2026, GILTI is rebranded NCTI, with a 40% deduction (effective ~12.6%) and 90% FTC allowance. In practice, if the Israeli company pays ~23% tax, little or no extra U.S. tax falls due. However, this regime adds complexity to cross-border cash flow. U.S. shareholders must file Forms 5471 and 965, and coordinate to maximize foreign tax credits.

Israeli tax law also has CFC rules (Sec.67), which could pull in foreign passive income of Israeli residents. CFOs should model both jurisdictions’ rules to avoid surprise double taxation.

BEAT and FTC Interactions

Large U.S. multinationals must consider the BEAT (Base Erosion Anti-Abuse Tax) when making deductible payments abroad. For example, excessive royalties or management fees to the Israeli parent could trigger a 10–12.5% minimum tax. Although startups are usually below the BEAT $500M threshold, any plan should minimize base-erosion payments. More generally, Israel and the U.S. allow foreign tax credits (to alleviate double tax), but note restrictions. Under U.S. tax law, foreign taxes paid by an Israeli sub on dividend income are creditable (subject to local credit baskets and 80–90% GILTI haircut). Under Israeli law, foreign taxes paid (e.g. to the U.S.) generally get a credit against Israeli tax on the same income. Mis-filing these can be an expensive mistake.

VAT/Indirect Taxes

Israel imposes 18% VAT on most domestic sales, with exports zero-rated. Registration is required if turnover exceeds ~₪100K/year, including cross-border services.

In the U.S., there’s no federal VAT, but state sales taxes apply. Post-Wayfair (2018), remote sellers must register and collect sales tax if sales exceed state thresholds. CFOs should track customer locations to ensure compliance and avoid back taxes.

Stock-Based Compensation

Cross-border stock awards require careful planning. In Israel, Section 102 options or RSUs are taxed at 25% capital gains if conditions are met; otherwise, ordinary rates (up to ~50%) apply. In the U.S., ISOs offer deferral and capital gains benefits, while NSOs are taxed as ordinary income at exercise.

Employees may owe tax in both countries, and employers must withhold and report locally. Filing requirements (e.g., Forms 3921/3922, Sec.83(b) elections) differ, so legal and tax teams should coordinate plan design across jurisdictions.

Exit/M&A Planning

Cross-border exits require careful tax planning. In Israel, share sales are generally taxed at 25% CGT for residents, while non-residents may be exempt with a certificate of exemption. Stock-for-stock exchanges can defer tax but require pre-approval (103K ruling). Certain intangibles, like know-how, may be taxed at 25%.

In the U.S., gains on Israeli company stock are typically capital gains (0–20%), with §367 rules potentially applying for rollovers. CFOs should involve tax counsel early, obtain necessary rulings, and structure deals with cash vs. stock implications in mind.